Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GL-S01
- Development stage
- Preclinical
- Lead developer
- GI Innovation
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
GL-S01 is a preclinical recombinant fusion protein developed by GILongevity, a subsidiary of GI Innovation, for the prevention and treatment of sarcopenia (age-related muscle loss). The candidate is engineered using the proprietary GI-SMART platform, which enables the design of multi-targeting fusion proteins with optimized half-lives and therapeutic efficacy. While the specific molecular targets of GL-S01 remain undisclosed, the therapy is intended to address the biological mechanisms of muscle wasting to improve physical function and quality of life in aging populations.
Beyond the preview
Go deeper on GL-S01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GL-S01.